Hardest PTCE Practice Questions — Can You Answer These?

Condition: Angioedema. Action: Immediate referral to the pharmacist and/or emergency services (911). Rationale: Angioedema is a rare but severe side effect of ACE inhibitors involving deep dermal and submucosal swelling. It is more common in Black patients and can lead to airway obstruction. Exam Strategy: Differentiate between a common side effect (dry cough) and a medical emergency (angioedema). While ARBs have a lower risk, they are often avoided if a patient had severe angioedema with an ACEI.

Significance: Reduced antihypertensive effect and increased risk of acute kidney injury (AKI). Rationale: NSAIDs (like Ibuprofen) inhibit prostaglandins, causing vasoconstriction of the afferent arteriole in the kidney. ARBs/ACEIs cause vasodilation of the efferent arteriole. Together, they significantly drop glomerular filtration pressure, potentially leading to renal failure. Exam Strategy: Monitor for OTC NSAID use in patients on RAAS-acting medications; this is a high-yield triple whammy risk when a diuretic is also added.

Example: Benazepril (Lotensin) vs. Benadryl (Diphenhydramine). Strategy: Use of Tall Man Lettering (beNAZEpril) and double-checking the NDC and indication. Rationale: Many ACE inhibitors have similar names or prefixes (e.g., Enalapril vs. Lisinopril). Confusion between a blood pressure med and an antihistamine can lead to severe hypotension or untreated allergic reactions. Exam Strategy: Knowledge of ISMP LASA lists is essential for the PTCB safety domain.

Reason: Presence of Nitrosamine impurities (specifically NDMA or NDEA). Rationale: These impurities are classified as probable human carcinogens. Recalls were triggered by changes in the manufacturing process of the active pharmaceutical ingredient (API) in certain overseas facilities. Exam Strategy: Technicians are responsible for monitoring recall notices and removing affected lot numbers from inventory immediately. PTCB may test your understanding of the technician's role in recall management.

Rationale: Renal Protection (Nephropathy prevention). ARBs (and ACEIs) dilate the efferent arteriole of the kidney, reducing intraglomerular pressure. This slows the progression of albuminuria (protein in urine) and diabetic kidney disease. Exam Strategy: ACEIs and ARBs are drugs of choice for patients with diabetes or chronic kidney disease (CKD) regardless of baseline blood pressure, provided they can tolerate the potassium-elevating effects.